Previous close | 30.48 |
Open | 30.56 |
Bid | 0.00 x 1000 |
Ask | 0.00 x 900 |
Day's range | 30.56 - 31.75 |
52-week range | 23.01 - 41.87 |
Volume | |
Avg. volume | 168,740 |
Market cap | 785.465M |
Beta (5Y monthly) | 1.34 |
PE ratio (TTM) | 46.56 |
EPS (TTM) | 0.66 |
Earnings date | 03 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 41.50 |
MINNEAPOLIS, May 01, 2024--Protolabs (NYSE: PRLB) highlights its critical work with BioDapt, a company that designs, manufactures, and distributes high-performance lower limb prosthetic equipment used for action sports and other activities with similar physical demands. This is just one of the many ways Protolabs positively impacts the world through its unique, hybrid digital manufacturing model that combines its own digital factories with a network of global manufacturing partners.
Proto Labs' (PRLB) first-quarter 2024 results are likely to reflect the impacts of lower order levels seen in the earlier part of the quarter.
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...